One of the pharma stocks engaged in radiopharmaceuticals, allergy immunotherapy, contract manufacturing, and drug discovery services. The stock has jumped 4.65 percent after reporting a 51.66 percent YOY increase in net profit.
Stock Price Movement
With a market capitalization of Rs. 15,275.06 crores, the share of Jubilant Pharmova Limited has reached an intraday high of Rs. 999.40 per equity share, rising nearly around 4.65 percent from its previous day’s close price of Rs. 954.95. Since then, the stock has retreated and is currently trading at Rs. 945.80 per equity share.
Q3 FY25 Result Walkthrough
Coming into the quarterly results of Jubilant Pharmova Limited, the company’s consolidated revenue from operations increased by 8.92 percent YOY, from Rs. 1665.2 crore in Q3 FY24 to Rs. 1813.7 crore in Q3 FY25, and grew by 4.10 percent QoQ from Rs. 1742.2 crore in Q2 FY25.
The company has received revenue from radiopharmacy by 45.97 percent (Rs. 841.2 crores), allergy immunotherapy by 9.51 percent (Rs. 174 crores), contract research, development, and manufacturing organisation by 16.33 percent (Rs. 298.8 crores), generics by 10.91 percent (Rs. 199.6 crore), and sterile injectables by 17.28 percent (Rs. 361.1 crore) in Q3 FY25.
In Q3 FY25, Jubilant Pharmova Limited’s consolidated net profit increased by 51.66 percent YOY, reaching Rs. 100.7 crore compared to Rs. 66.4 crore during the same period last year. As compared to Q2 FY25, the net profit has decreased by 1.75 percent, from Rs. 102.5 crore.
The basic earnings per share increased by 50.95 percent and stood at Rs 6.37 as against Rs 4.22 recorded in the same quarter in the previous year 2024.
Also read….
Partnership
Jubilant Biosys, through its subsidiary JBIRSPL, has teamed up with Pierre Fabre to buy 80% of Jasmin, a French R&D company. This partnership helps Jubilant expand in Europe, focusing on biologics, antibody treatments, and drug discovery services.
New product launches
The company plans to launch six to eight products annually in both US and international markets. It has 33 ANDAs in the approval pipeline for the US, with 3 approved in FY25. The company is ramping up exports to the US from its Roorkee facility and has started supplying products from contract manufacturing partners to the US market.
Future Outlook
The company plans to invest USD 50 million to expand its network to nine sites, securing long-term contracts with top manufacturers. The radio pharmacies will become operational by FY28, contributing significantly to revenue and profitability, with an expected RoCE of over 20%.
Product Pipeline
The company has a strong product pipeline in both the SPECT and PET categories, with an addressable market of approximately USD 50 million and USD 500 million, respectively in the medium term. Additionally, in the therapeutic segment, the company is focusing on the development of MIBG.
Written By – Nikhil Naik
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
